



C3HeB/FeJ HCC Has Tumor Characteristics Similar to Human HCC	
Tumor Characteristic	Human HCC C3HeB/FeJ HCC
More prevalent in males	++ +++
Occurs later in life	++ ++
Variable size	++ ++
Variable location in liver	++ ++
Multiple foci	++ ++
Hepatosteatosis	++ ++
Cirrhosis/fibrosis	+++ +
Progression from dysplasia to vasci invasion	ular
Biomakers (p53, GP3, HSP70, AFP	),
TGFβ1)	
No single gene drives majority of tu	imors ++ ++






### C3HeB/FeJ HCC Has Tumor Characteristics Similar to Human HCC Human HCC C3HeB/FeJ HCC **Tumor Characteristic** More prevalent in males +++ Occurs later in life Variable size Variable location in liver ++ ++ Multiple foci ++ Hepatosteatosis ++ Cirrhosis/fibrosis +++ + Progression from dysplasia to vascular ++ Biomakers (p53, GP3, HSP70, AFP,

++

++


No single gene drives majority of tumors




## Temozolomide (TMZ) as an Anti-cancer Agent


- · First line therapy for glioblastoma
- O<sup>6</sup>-methylguanine DNA methyltransferase (MGMT) expression affects susceptibility
  - TMZ induces lesions which are repaired by MGMT
  - Highly mutagenic and cytotoxic if unrepaired
  - Overexpression is associated with therapy resistance
- MGMT is silenced in 40% of human HCC through promoter hypermethylation


Int J Cancer (2003) 103:440-444




Do SAHA and TMZ synergistically reduce cell viability *in vitro*?














Do SAHA and TMZ synergistically reduce tumor burden *in vivo*?























# DMSO: Innocuous?

- · Considered non-toxic by EPA
- Frequently used as a solvent for chemicals with poor solubility and as a cryopreservative in the laboratory
- FDA approved as a cryopreservative for bone marrow transplants, to treat cystitis, and off label use for extravasation side effect of chemotherapy infusions
- 10% DMSO is synergistic with several chemotherapies in ovarian cancer primary cells

Ann Oncol (2004) 25(6):858-62 Am J of Obstet Gynecol (1988) 159(4): 848-52

# Hypothetical Model of DMSO Action in HCC O: O: MethylpurineDNA Glycosylase MPG Excision Repair Apoptosis Apoptosis

## Conclusions To Date

- 1. SAHA and TMZ synergistically reduce viability of 2 HCC cell lines *in vitro*.
- TMZ (in DMSO) and DMSO significantly reduce total tumor burden in C3HeB/FeJ HCC, but some tumors do not respond to treatment.
- 3. SNU398 is more sensitive to both DMSO and TMZ compared to Huh7.

# Acknowledgements

Walter Lab Kim Hildreth Guogang Xu, MD PhD Jamila Sanchez, PhD Maryanne Herzig, PhD Rebecca Garcia

Department of Radiology
MD/PhD Program
Tyler Curiel for the use of his VisualSonics
Vevo770 Ultrasound

LuZhe Sun for cell lines and use of Countess Cell Counter

Robert Lanford for cell lines Ellen Kraig for use of cell culture facilities Committee Members Christi Walter, PhD LuZhe Sun, PhD Sunil Ahuja, MD Robert Marciniak, MD PhD Feyruz Rassool, PhD (University of Maryland)

Collaborators Hugh White, MD Michael Drake, DVM PhD

<u>Funding</u> CPRIT Predoctoral Fellowship (RP140105)